CollabRx and OncoDNA announce multi-year agreement
CollabRx and OncoDNA, SA today announced a multi-year agreement to purchase CollabRx SaaS-based technology and content resources to be used in conjunction with OncoDNA's cancer mutation panels.
OncoGenex Pharmaceuticals, Inc. announced today that it has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission and an MJDS prospectus under the multi-jurisdictional disclosure system in the Province of British Columbia.